WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The new Pharmacor report entitled Schizophrenia finds that the patent expiries of Janssen's Risperdal Consta and Invega, AstraZeneca's Seroquel, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify, Eli Lilly's Zyprexa and Pfizer's Geodon/Zeldox will be the key factors driving a 20 percent decrease in the overall schizophrenia drug market. However, as a result of the uptake of emerging therapies -- primarily depot formulations -- the market will increase modestly from $5.2 billion in 2013 to $5.6 billion in 2018.
The launch of new depot formulations of atypical antipsychotics will partially offset the decline in the schizophrenia market and will offer more-convenient treatment options for patients. Janssen's depot formulation of Invega, Invega Sustenna, will experience the greatest market success of all depot formulations, with peak-year major-market sales in excess of $500 million.
"Depot formulations such as Invega Sustenna will offer advantages in dosing and administration compared with the only marketed atypical depot formulation -- Janssen's Risperdal Consta," said Decision Resources Analyst Sandra Chow, M.Sc. "Emerging depot formulations will command premium pricing and, in 2018, will account for nearly one-third of the overall schizophrenia drug market."
Interviewed experts indicate that because most current antipsychotics function through similar mechanisms of action and are not completely effective in all patients, the development of therapies with novel mechanisms of action remains a key unmet need in schizophrenia treatment. Eli Lilly's LY-2140023 will be the first agent with a novel mechanism of action to reach the market, launching in 2013 in the United States and in 2014 in Europe. The report finds that LY-2140023, which will be largely used in conjunction with currently available agents, will provide physicians with an effective new treatment option for patients inadequately controlled on other antipsychotic regimens.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
SOURCE Decision Resources
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved